TY - JOUR
T1 - Outcomes of Care Among Patients With Gout in Europe
T2 - A Cross-sectional Survey
AU - Te Kampe, Ritch
AU - Jansen, Tim L
AU - van Durme, Caroline
AU - Janssen, Matthijs
AU - Petersen, Gudula
AU - Boonen, Annelies
N1 - Funding Information:
The data collection for this study was funded by Grünenthal GmbH. 1R. te Kampe, MSc, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, and Department of Rheumatology, VieCuri Medical Center, Venlo, the Netherlands; 2T.L. Jansen, MD, PhD, M. Janssen, MD, PhD, Department of Rheumatology, VieCuri Medical Center, Venlo, the Netherlands; 3C. van Durme, MD, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands, and Centre Hospitalier Chrétien, Liège, Belgium; 4G. Petersen, PhD, Grünenthal GmbH, Aachen, Germany; 5A. Boonen, Professor, MD, PhD, Department of Internal Medicine, Maastricht University Medical Center, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands. GP is a full-time employee in the department of Governmental Affairs & Patient Centricity at Grünenthal GmbH. Address correspondence to R. te Kampe, Department of Rheumatology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ Maastricht, the Netherlands. Email: [email protected]. Accepted for publication May 28, 2021.
Funding Information:
The data collection for this study was funded by Gr?nenthal GmbH.
Publisher Copyright:
© 2022 The Journal of Rheumatology.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - OBJECTIVE: To assess health- and patient-centered outcomes in gout across Europe, and explore patient-, care-, and country-level characteristics associated with these outcomes.METHODS: Patients with self-reported physician-diagnosed gout from 14 European countries completed an online survey. Multivariable mixed-effect logistic and linear regressions were computed for health outcomes (gout flare recurrence) and patient-centered outcomes (patient satisfaction with current medication, and unaddressed goals), accounting for clustering within countries. The role of patient-, care-, and country-level factors was explored.RESULTS: Participants included 1029 patients, predominantly diagnosed by a general practitioner (GP). One or more gout flares were reported by 70% of patients and ≥ 3 flares by 32%. Gout patients reported 1.1 ± 1.2 unaddressed goals, and 80% were satisfied with current medication. Patients with ≥ 3 and ≥ 1 flares were less likely to be treated with urate-lowering therapy (ULT) (OR 0.52, 95% CI 0.39-0.70 and OR 0.38, 95% CI 0.28-0.53, respectively), but more likely to have regular physician visits (OR 2.40, 95% CI 1.79-3.22 and OR 1.77, 95% CI 1.30-2.41). Three or more gout flares were also associated with lower satisfaction (OR 0.39, 95% CI 0.28-0.56) and more unaddressed goals (β 0.36, 95% CI 0.19-0.53). Notwithstanding, the predicted probability of being satisfied was still between 57% and 75% among patients with ≥ 3 flares but who were not receiving ULT. Finally, patients from wealthier and Northern European countries more frequently had ≥ 3 gout flares.CONCLUSION: Across Europe, many patients with gout remain untreated despite frequent reported flares. Remarkably, a substantial proportion of them were still satisfied with gout management. A better understanding of patients' satisfaction and its role in physicians' gout management decisions is warranted to improve quality of care and gout outcomes across Europe.
AB - OBJECTIVE: To assess health- and patient-centered outcomes in gout across Europe, and explore patient-, care-, and country-level characteristics associated with these outcomes.METHODS: Patients with self-reported physician-diagnosed gout from 14 European countries completed an online survey. Multivariable mixed-effect logistic and linear regressions were computed for health outcomes (gout flare recurrence) and patient-centered outcomes (patient satisfaction with current medication, and unaddressed goals), accounting for clustering within countries. The role of patient-, care-, and country-level factors was explored.RESULTS: Participants included 1029 patients, predominantly diagnosed by a general practitioner (GP). One or more gout flares were reported by 70% of patients and ≥ 3 flares by 32%. Gout patients reported 1.1 ± 1.2 unaddressed goals, and 80% were satisfied with current medication. Patients with ≥ 3 and ≥ 1 flares were less likely to be treated with urate-lowering therapy (ULT) (OR 0.52, 95% CI 0.39-0.70 and OR 0.38, 95% CI 0.28-0.53, respectively), but more likely to have regular physician visits (OR 2.40, 95% CI 1.79-3.22 and OR 1.77, 95% CI 1.30-2.41). Three or more gout flares were also associated with lower satisfaction (OR 0.39, 95% CI 0.28-0.56) and more unaddressed goals (β 0.36, 95% CI 0.19-0.53). Notwithstanding, the predicted probability of being satisfied was still between 57% and 75% among patients with ≥ 3 flares but who were not receiving ULT. Finally, patients from wealthier and Northern European countries more frequently had ≥ 3 gout flares.CONCLUSION: Across Europe, many patients with gout remain untreated despite frequent reported flares. Remarkably, a substantial proportion of them were still satisfied with gout management. A better understanding of patients' satisfaction and its role in physicians' gout management decisions is warranted to improve quality of care and gout outcomes across Europe.
KW - gout
KW - healthcare surveys
KW - multilevel analysis
KW - patient-reported outcome measures
KW - quality of healthcare
KW - BASE-LINE FINDINGS
KW - QUALITY-OF-LIFE
KW - MANAGEMENT
KW - PREVALENCE
KW - SATISFACTION
KW - VALIDATION
KW - KNOWLEDGE
KW - THERAPY
KW - COUNTRY
KW - DISEASE
U2 - 10.3899/jrheum.210009
DO - 10.3899/jrheum.210009
M3 - Article
C2 - 34329184
SN - 0315-162X
VL - 49
SP - 312
EP - 319
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 3
ER -